Single Point Partners LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 12.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,234 shares of the biopharmaceutical company’s stock after selling 1,936 shares during the period. Single Point Partners LLC’s holdings in Pfizer were worth $465,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Corbett Road Capital Management LLC purchased a new stake in Pfizer during the second quarter valued at about $25,000. New England Investment & Retirement Group Inc. bought a new position in shares of Pfizer during the first quarter valued at about $26,000. Lion Street Advisors LLC bought a new position in shares of Pfizer during the first quarter valued at about $27,000. Reitz Capital Advisors LLC bought a new position in shares of Pfizer during the second quarter valued at about $29,000. Finally, Benjamin Edwards Inc. grew its stake in shares of Pfizer by 49.8% during the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 335 shares during the last quarter. Institutional investors and hedge funds own 70.20% of the company’s stock.
A number of equities research analysts have commented on the stock. Royal Bank of Canada reaffirmed a “buy” rating and issued a $43.00 target price on shares of Pfizer in a research report on Monday, July 20th. Barclays cut their target price on shares of Pfizer from $37.00 to $35.00 in a research report on Monday, June 1st. ValuEngine downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday. SVB Leerink lifted their target price on shares of Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a research report on Wednesday. Finally, Piper Sandler boosted their price objective on shares of Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $38.95.
Pfizer stock traded down $0.26 during mid-day trading on Friday, hitting $38.48. The stock had a trading volume of 27,042,691 shares, compared to its average volume of 32,108,124. The firm has a market capitalization of $213.75 billion, a P/E ratio of 15.27, a P/E/G ratio of 3.12 and a beta of 0.68. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.56. The firm’s 50 day moving average is $34.75 and its 200 day moving average is $35.79. Pfizer Inc. has a one year low of $27.88 and a one year high of $40.97.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.10%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.80 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be paid a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 3.95%. The ex-dividend date of this dividend is Thursday, July 30th. Pfizer’s payout ratio is currently 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: What does a market perform rating mean?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.